Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Journal of Thoracic Oncology
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer | British Journal of Cancer
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling | Science
What Is MET? - MET Crusaders
Cancers | Free Full-Text | Targeting MET Amplification as a New Oncogenic Driver | HTML
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? - Cancer Treatment Reviews
Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
C-Met - Wikipedia
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. - Abstract - Europe PMC
Antonio Passaro on Twitter: "Great slides @ChristianRolfo on diagnostic challenges on MET amplification. #biomarker #lcsm #LungCancer… "
Resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer and strategies to overcome it | Australian Medical Student Journal
Read in JCO:... - American Society of Clinical Oncology | Facebook
MET amplification causes EGFR-TKI resistance by activating... | Download Scientific Diagram
MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer - Journal of Thoracic Oncology
Genes - Mass General Cancer Center
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib - Lung Cancer
EMT, MET amplification, and IGF-1R confer resistance to EGFR TKIs.... | Download Scientific Diagram
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
MET-dependent solid tumours — molecular diagnosis and targeted therapy | Nature Reviews Clinical Oncology
